Browsing Tag
Avenue Capital Group
3 posts
Citius Oncology (CTOR) balances LYMPHIR launch momentum with cash runway pressure after Q2 loss
Citius Oncology has LYMPHIR revenue, but cash runway only reaches November 2026. Investors now face launch proof versus dilution risk.
Citius Oncology (CTOR) stock in focus as $36.5m financing targets LYMPHIR commercialization
Citius Oncology has capital and an approved CTCL drug. The harder question is whether LYMPHIR can turn niche oncology promise into revenue.
SpiceJet signs MoU with Avenue Capital Group pertaining to 50 new aircraft
Indian domestic airline SpiceJet has inked a memorandum of understanding (MoU) with Avenue Capital Group for financing, acquisition,…